دورية أكاديمية
أعرض في EDS

Treatment planning for photodynamic therapy of abscess cavities using patient-specific optical properties measured prior to illumination.

التفاصيل البيبلوغرافية
العنوان: Treatment planning for photodynamic therapy of abscess cavities using patient-specific optical properties measured prior to illumination.
المؤلفون: Li Z; Department of Biomedical Engineering, University of Rochester, Rochester, NY, United States of America., Hannan MN; Department of Physics and Astronomy, University of Rochester, Rochester, NY, United States of America., Sharma AK; Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, United States of America., Baran TM; Department of Biomedical Engineering, University of Rochester, Rochester, NY, United States of America.; Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, United States of America.; The Institute of Optics, University of Rochester, Rochester, NY, United States of America.
المصدر: Physics in medicine and biology [Phys Med Biol] 2024 Feb 28; Vol. 69 (5). Date of Electronic Publication: 2024 Feb 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: IOP Publishing Country of Publication: England NLM ID: 0401220 Publication Model: Electronic Cited Medium: Internet ISSN: 1361-6560 (Electronic) Linking ISSN: 00319155 NLM ISO Abbreviation: Phys Med Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Bristol : IOP Publishing
مواضيع طبية MeSH: Photochemotherapy*/methods, Humans ; Lighting ; Abscess/diagnostic imaging ; Abscess/drug therapy ; Retrospective Studies ; Light ; Photosensitizing Agents/therapeutic use
مستخلص: Photodynamic therapy (PDT) is an effective antimicrobial therapy that we used to treat human abscess cavities in a Phase 1 clinical trial. This trial included pre-PDT measurements of abscess optical properties, which affect light dose (light fluence) at the abscess wall and PDT response. This study simulated PDT treatment planning for 13 subjects that received optical spectroscopy prior to clinical PDT, to determine the impact of measured optical properties on ability to achieve fluence rate targets in 95% of the abscess wall. Retrospective treatment plans were evaluated for 3 conditions: (1) clinically delivered laser power and assumed, homogeneous optical properties, (2) clinically delivered laser power and measured, homogeneous optical properties, and (3) with patient-specific treatment planning using measured, homogeneous optical properties. Treatment plans modified delivered laser power, intra-cavity Intralipid (scatterer) concentration, and laser fiber type. Using flat-cleaved laser fibers, the proportion of subjects achieving 95% abscess wall coverage decreased significantly relative to assumed optical properties when using measured values for 4 mW cm -2 (92% versus 38%, p = 0.01) and 20 mW cm -2 (62% versus 15%, p = 0.04) thresholds. When measured optical properties were incorporated into treatment planning, the 4 mW cm -2 target was achieved for all cases. After treatment planning, optimal Intralipid concentration across subjects was 0.14 ± 0.09%, whereas 1% was used clinically. Required laser power to achieve the 4 mW cm -2 target was significantly correlated with measured abscess wall absorption ( ρ = 0.7, p = 0.008), but not abscess surface area ( ρ = 0.2, p = 0.53). When using spherical diffuser fibers for illumination, both optimal Intralipid concentration ( p = 0.0005) and required laser power ( p = 0.0002) decreased compared to flat cleaved fibers. At 0% Intralipid concentration, the 4 mW cm -2 target could only be achieved for 69% of subjects for flat-cleaved fibers, compared to 100% for spherical diffusers. Based on large inter-subject variations in optical properties, individualized treatment planning is essential for abscess photodynamic therapy. (Clinical Trial Registration: The parent clinical trial from which these data were acquired is registered on ClinicalTrials.gov as 'Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities,' with ClinicalTrials.gov identifier NCT02240498).
(Creative Commons Attribution license.)
التعليقات: Update of: medRxiv. 2023 Nov 06;:. (PMID: 37961683)
References: Photochem Photobiol. 2020 Mar;96(2):310-319. (PMID: 31556122)
Lasers Surg Med. 2007 Sep;39(8):647-53. (PMID: 17886277)
Proc SPIE Int Soc Opt Eng. 2023 Jan-Feb;12358:. (PMID: 37771524)
AJR Am J Roentgenol. 2010 Mar;194(3):815-20. (PMID: 20173165)
Proc SPIE Int Soc Opt Eng. 2023 Jan-Feb;12359:. (PMID: 37860151)
J Biomed Opt. 2005 Jan-Feb;10(1):14004. (PMID: 15847585)
Lasers Surg Med. 2009 Nov;41(9):612-21. (PMID: 19827147)
Photodiagnosis Photodyn Ther. 2011 Jun;8(2):75-85. (PMID: 21497298)
Med Phys. 2021 Jul;48(7):3721-3729. (PMID: 33906264)
Appl Opt. 1991 Nov 1;30(31):4507-14. (PMID: 20717241)
Photodiagnosis Photodyn Ther. 2016 Mar;13:10-14. (PMID: 26592336)
Biomed Opt Express. 2021 Aug 04;12(9):5401-5422. (PMID: 34692191)
J Surg Res. 1995 Dec;59(6):658-65. (PMID: 8538162)
Med Phys. 2007 Nov;34(11):4309-21. (PMID: 18072496)
J Biomed Opt. 2020 Jun;25(6):1-13. (PMID: 32529817)
Photodiagnosis Photodyn Ther. 2023 Mar;41:103237. (PMID: 36496126)
Adv Drug Deliv Rev. 2021 Oct;177:113941. (PMID: 34419503)
Med Phys. 2005 Dec;32(12):3524-36. (PMID: 16475751)
Biomed Opt Express. 2016 Oct 21;7(11):4685-4694. (PMID: 27896007)
Phys Med Biol. 1994 Jun;39(6):947-59. (PMID: 15551572)
Med Phys. 2019 Jul;46(7):3259-3267. (PMID: 31056771)
J Am Coll Surg. 2010 Jun;210(6):975-83. (PMID: 20510807)
Radiother Oncol. 1995 Nov;37(2):131-5. (PMID: 8747937)
AJR Am J Roentgenol. 2004 Feb;182(2):463-6. (PMID: 14736682)
Photodiagnosis Photodyn Ther. 2021 Mar;33:102136. (PMID: 33307236)
J Biomed Opt. 2022 Feb;27(8):. (PMID: 35146973)
Photodiagnosis Photodyn Ther. 2016 Mar;13:120-122. (PMID: 26732393)
Lasers Surg Med. 2013 Oct;45(8):509-16. (PMID: 23996629)
Photochem Photobiol Sci. 2004 May;3(5):436-50. (PMID: 15122361)
J Biomed Opt. 2024 Feb;29(2):027002. (PMID: 38414658)
mSphere. 2021 Jan 6;6(1):. (PMID: 33408223)
Eur J Radiol. 2002 Sep;43(3):204-18. (PMID: 12204403)
World J Surg. 2001 Mar;25(3):362-9; discussion 370-2. (PMID: 11343195)
Lasers Surg Med. 1996;18(2):139-49. (PMID: 8833282)
Dermatology. 2009;218(3):193-202. (PMID: 19077380)
Photochem Photobiol. 2020 Mar;96(2):405-416. (PMID: 31907934)
Photodiagnosis Photodyn Ther. 2011 Mar;8(1):64-7. (PMID: 21333937)
Ann Thorac Surg. 2012 May;93(5):1658-65; discussion 1665-7. (PMID: 22541196)
Am J Pathol. 2015 Jun;185(6):1518-27. (PMID: 25749135)
Biomed Opt Express. 2021 Nov 09;12(12):7388-7404. (PMID: 35003841)
J Biomed Opt. 2011 Aug;16(8):085003. (PMID: 21895311)
J Biophotonics. 2011 Nov;4(11-12):773-87. (PMID: 22167862)
معلومات مُعتمدة: R01 EB029921 United States EB NIBIB NIH HHS
فهرسة مساهمة: Keywords: Monte Carlo simulation; abscess; clinical trial; methylene blue; photodynamic therapy
سلسلة جزيئية: ClinicalTrials.gov NCT02240498
المشرفين على المادة: 0 (Photosensitizing Agents)
تواريخ الأحداث: Date Created: 20240205 Date Completed: 20240229 Latest Revision: 20240301
رمز التحديث: 20240301
مُعرف محوري في PubMed: PMC10900070
DOI: 10.1088/1361-6560/ad2635
PMID: 38316055
قاعدة البيانات: MEDLINE
الوصف
تدمد:1361-6560
DOI:10.1088/1361-6560/ad2635